Iterum: FDA Accepts Resubmission Of NDA For Oral Sulopenem rttnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from rttnews.com Daily Mail and Mail on Sunday newspapers.
Iterum Therapeutics plc Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy.
The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical.
Brainstorm Cell Therapeutics Announces First Quarter 2024 Financial Results And Provides Corporate Update menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.